Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group
Blood(2021)
摘要
Introduction: Mantle cell lymphoma (MCL) is usually an aggressive B-cell lymphoma subtype characterized by frequent relapses and is still considered to be incurable. Ibrutinib (iBTK), a first-in-class inhibitor of Bruton′s tyrosine kinase, demonstrated promising outcomes in heavily pretreated MCL patients in several prospective trials. But only limited data on its effect is available in real-world population.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要